🚨 GROUNDBREAKING STUDY IN PHARMACEUTICS UNCOVERS 115,100% SURGE IN DEADLY HEART CONDITIONS FROM COVID mRNA VACCINES!
Published in Pharmaceutics (Volume 17, Issue 4) by MDPI, this explosive peer-reviewed study, led by a world-renowned immunologist from Semmelweis University and Sungkyunkwan University, analyzed data from 85 million people, making it one of the largest vaccine safety investigations ever conducted.
The findings are staggering: COVID mRNA vaccines triggered a 284% spike in heart attacks after the second dose, a 234% surge in strokes post-first dose, and a 199% increase in arrhythmias following the first dose.
Coronary artery disease cases skyrocketed after the second dose, with some cardiac events soaring by an unprecedented 115,100% compared to pre-vaccination baselines.
Drawing from the US Vaccine Adverse Event Reporting System (VAERS) and global datasets, the study revealed a 26-fold increase in adverse events (AEs) compared to flu vaccines, with severe “Brighton-listed” AEs like myocarditis surging 1152x, thrombosis 455x, and myocardial infarction 218x higher.
Nearly every organ system is impacted, with young men aged 16-25 facing the highest risk of myocarditis, a potentially fatal heart inflammation, alongside pericarditis and other cardiovascular issues peaking weeks after vaccination.
The study redefines mRNA vaccines as “prophylactic immuno-gene therapies,” warning that chronic, disabling AEs may constitute “iatrogenic orphan diseases”— rare conditions caused by medical intervention.
Despite fewer than 10,000 cumulative US cases of chronic AEs like myocarditis as of May 2023, underreporting is suspected, with links to excess deaths globally.
The research critiques lipid nanoparticle (LNP) technology, highlighting its role in immune overstimulation and potential toxicity from spike protein production, alongside risks from contaminants like plasmid DNA and PEG immunogenicity.
It traces AE statistics from initial underestimations to recent data suggesting widespread harm, challenging claims of “rare” side effects.
